• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 6:20:31 AM ET
    $PAND
    Get the next $PAND alert in real time by email
    SC 13G/A 1 d132418dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

     

     

    PANDION THERAPEUTICS, INC.

    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    698340106

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☒

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

     

     

     


    CUSIP No. 698340106    Schedule 13G    Page 2 of 10

     

      1.    

      NAME OF REPORTING PERSON

     

      AI Pan LLC

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY:

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION:

     

      State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    BY OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         5.     

      SOLE VOTING POWER:

     

      0

         6.   

      SHARED VOTING POWER:

     

      2,827,883

         7.   

      SOLE DISPOSITIVE POWER:

     

      0

         8.   

      SHARED DISPOSITIVE POWER:

     

      2,827,883

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

      2,827,883

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

      9.6%(1)

    12.  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

      OO (Limited Liability Company)

     

    (1)

    Based on 29,519,902 shares of the Issuer’s Common Stock as of November 12, 2020, as reported in the Issuer’s quarterly report on Form 10-Q for the quarter ended September 30, 2020, as filed with the Securities and Exchange Commission (the “SEC”) on November 16, 2020.

     

    2 of 10


    CUSIP No. 698340106    Schedule 13G    Page 3 of 10

     

      1.    

      NAME OF REPORTING PERSON

     

      Access Industries Holdings LLC

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY:

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION:

     

      State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    BY OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         5.     

      SOLE VOTING POWER:

     

      0

         6.   

      SHARED VOTING POWER:

     

      2,827,883

         7.   

      SOLE DISPOSITIVE POWER:

     

      0

         8.   

      SHARED DISPOSITIVE POWER:

     

      2,827,883

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

      2,827,883

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

      9.6% (1)

    12.  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

      OO (Limited Liability Company)

     

    (1)

    Based on 29,519,902 shares of the Issuer’s Common Stock as of November 12, 2020, as reported in the Issuer’s quarterly report on Form 10-Q for the quarter ended September 30, 2020, as filed with the SEC on November 16, 2020.

     

    3 of 10


    CUSIP No. 698340106    Schedule 13G    Page 4 of 10

     

      1.    

      NAME OF REPORTING PERSON

     

      Access Industries Management, LLC

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY:

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION:

     

      State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    BY OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         5.     

      SOLE VOTING POWER:

     

      0

         6.   

      SHARED VOTING POWER:

     

      2,827,883

         7.   

      SOLE DISPOSITIVE POWER:

     

      0

         8.   

      SHARED DISPOSITIVE POWER:

     

      2,827,883

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

      2,827,883

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

      9.6% (1)

    12.  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

      OO (Limited Liability Company)

     

    (1)

    Based on 29,519,902 shares of the Issuer’s Common Stock as of November 12, 2020, as reported in the Issuer’s quarterly report on Form 10-Q for the quarter ended September 30, 2020, as filed with the SEC on November 16, 2020.

     

    4 of 10


    CUSIP No. 698340106    Schedule 13G    Page 5 of 10

     

      1.    

      NAME OF REPORTING PERSON

     

      Len Blavatnik

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY:

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION:

     

      United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    BY OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         5.     

      SOLE VOTING POWER:

     

      0

         6.   

      SHARED VOTING POWER:

     

      2,827,883

         7.   

      SOLE DISPOSITIVE POWER:

     

      0

         8.   

      SHARED DISPOSITIVE POWER:

     

      2,827,883

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

      2,827,883

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

      9.6% (1)

    12.  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

      IN

     

    (1)

    Based on 29,519,902 shares of the Issuer’s Common Stock as of November 12, 2020, as reported in the Issuer’s quarterly report on Form 10-Q for the quarter ended September 30, 2020, as filed with the SEC on November 16, 2020.

     

    5 of 10


    CUSIP No. 698340106    Schedule 13G    Page 6 of 10

     

    Item 1

        

     

      (a)

    Name of Issuer:

     

          

    Pandion Therapeutics, Inc. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

     

          

    134 Coolidge Avenue

          

    Watertown, Massachusetts 02472

     

    Item 2

     

      (a)

    Name of Person Filing:

    Each of the following is referred to herein as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

     

          

    AI Pan LLC

          

    Access Industries Holdings LLC

          

    Access Industries Management, LLC

          

    Len Blavatnik

     

      (b)

    Address of Principal Business Office or, if none, Residence:

     

          

    The address of each of the Reporting Persons is:

    c/o Access Industries, Inc.

    40 West 57th Street, 28th Floor

    New York, NY 10019

     

      (c)

    Citizenship:

     

          

    Mr. Blavatnik is a citizen of the United States of America. Each of the other Reporting Persons is organized under the laws of the State of Delaware.

     

      (d)

    Title of Class of Securities:

     

          

    Common stock, par value $0.001 per share (“Common Stock”)

     

      (e)

    CUSIP Number:

     

          

    698340106

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    6 of 10


    CUSIP No. 698340106    Schedule 13G    Page 7 of 10

     

    Item 4.

    Ownership.

    (a-c)

    The ownership information presented below represents beneficial ownership of the Issuer’s Common Stock as of December 31, 2020, based on 29,519,902 shares of the Issuer’s Common Stock as of November 12, 2020, as reported in the Issuer’s quarterly report on Form 10-Q for the quarter ended September 30, 2020.

     

    Reporting Person   

    Amount

    beneficially

    owned

        

    Percent

    of class:

        Sole
    power
    to vote
    or to
    direct
    the
    vote:
         Shared
    power to
    vote or to
    direct the
    vote:
        

    Sole
    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    AI Pan LLC

         2,827,883        9.6 %      0        2,827,883        0        2,827,883  

    Access Industries Holdings LLC

         2,827,883        9.6 %      0        2,827,883        0        2,827,883  

    Access Industries Management, LLC

         2,827,883        9.6 %      0        2,827,883        0        2,827,883  

    Len Blavatnik

         2,827,883        9.6 %      0        2,827,883        0        2,827,883  

    Each of Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik may be deemed to beneficially own the shares of the Issuer’s Common Stock beneficially owned by AI Pan LLC, a subsidiary in a multi-tier corporate structure of which Access Industries Holdings LLC is the parent holding company and is ultimately managed by Access Industries Management, LLC and controlled by Mr. Blavatnik.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below the Reporting Persons certify that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Exchange Act Rule 14a-11.

     

    7 of 10


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 15, 2021

    AI PAN LLC

     

    By:   Access Industries Management, LLC, Its Manager

     

    /s/ Alejandro Moreno

    Signature

    Alejandro Moreno / Executive Vice President

    Name/Title

    ACCESS INDUSTRIES HOLDINGS LLC

     

    By:   Access Industries Management, LLC, Its Manager

     

    /s/ Alejandro Moreno

    Signature

    Alejandro Moreno / Executive Vice President

    Name/Title

    ACCESS INDUSTRIES MANAGEMENT, LLC

     

    By:  

     

    /s/ Alejandro Moreno

    Signature

    Alejandro Moreno / Executive Vice President

    Name/Title

    *

    Signature

    Len Blavatnik

    Name

     

    *

    The undersigned, by signing his name hereto, executes this Schedule 13G on behalf of Mr. Blavatnik pursuant to the Limited Power of Attorney filed with the Securities and Exchange Commission on July 24, 2020.

     

    By:  

    /s/ Alejandro Moreno

    Name:   Alejandro Moreno
      Attorney-in-Fact
    Get the next $PAND alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PAND

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SVB Leerink resumed coverage on Pandion Therapeutics with a new price target

      SVB Leerink resumed coverage of Pandion Therapeutics with a rating of Market Perform and set a new price target of $60.00

      3/4/21 8:24:57 AM ET
      $PAND
    • Morgan Stanley resumed coverage on Pandion Therapeutics with a new price target

      Morgan Stanley resumed coverage of Pandion Therapeutics with a rating of Equal Weight and set a new price target of $60.00 from $25.00 previously

      3/4/21 8:24:08 AM ET
      $PAND
    • Pandion Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Pandion Therapeutics from Overweight to Equal-Weight and set a new price target of $60.00 from $25.00 previously

      2/26/21 9:18:02 AM ET
      $PAND

    $PAND
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merck Completes Acquisition of Pandion Therapeutics

      KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND) at a purchase price of $60 per share. As of the tender offer expiration, 27,770,123 shares of common stock of Pandion were validly tendered and not withdrawn from the tender offer, representing approximately 88.6% percent of the outstanding common stock of Pandion on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck exp

      4/1/21 8:30:00 AM ET
      $PAND
    • Merck Begins Tender Offer to Acquire Pandion Therapeutics

      KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND). On Feb. 25, 2021, Merck announced its intent to acquire Pandion. Upon the successful closing of the tender offer, stockholders of Pandion will receive $60 in cash for each share of Pandion common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following the purchase of shares in the tender offer, Pandion will become a subsidiary of Merck. Merck will

      3/4/21 6:45:00 AM ET
      $MRK
      $PAND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck to Acquire Pandion Therapeutics

      KENILWORTH, N.J & WATERTOWN, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. This represents an approximate total equity value of $1.85 billion. “This acquisition builds upon Merck’s strategy to identify and secure candidates with differentiated and potentially foundational charac

      2/25/21 6:45:00 AM ET
      $MRK
      $PAND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PAND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pandion Therapeutics Inc. (Amendment)

      SC 13G/A - Pandion Therapeutics, Inc. (0001807901) (Subject)

      5/17/21 4:35:46 PM ET
      $PAND
    • SEC Form SC 13D/A filed by Pandion Therapeutics Inc. (Amendment)

      SC 13D/A - Pandion Therapeutics, Inc. (0001807901) (Subject)

      4/8/21 5:24:29 PM ET
      $PAND
    • SEC Form SC 13D/A filed by Pandion Therapeutics Inc. (Amendment)

      SC 13D/A - Pandion Therapeutics, Inc. (0001807901) (Subject)

      4/2/21 9:54:00 AM ET
      $PAND

    $PAND
    Leadership Updates

    Live Leadership Updates

    See more
    • NodThera Appoints Chief Medical Officer and Chief Financial Officer

      CAMBRIDGE, England & BOSTON & SEATTLE--(BUSINESS WIRE)--NodThera, a biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat chronic inflammation, today announced the expansion of its senior leadership team with the appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton, J.D., MBA, as Chief Financial Officer. Dr. Johns is an accomplished drug development leader and board-certified clinical neurologist who previously served as Chief Medical Officer and Executive Vice President of Medical and Scientific Affairs at Syntimmune, prior to the company’s acquisition by Alexion Pharmaceuticals. Ms. Dorton is a recognized

      12/15/20 8:00:00 AM ET
      $PAND
      $FULC
      $ECOL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Environmental Services
      Public Utilities
    • Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

      WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A., to Pandion’s board of directors and as chair of the audit committee. Ms. Dorton assumes the position of chair of the audit committee from Christopher Fuglesang, Ph.D., J.D., who will continue to serve as a member of the board and audit committee. Mitchell Mutz, Ph.D., resigned from the Company’s board on December 2, 2020. “Ms. Dorton brings to Pandion over two decades of financial expe

      12/3/20 8:00:00 AM ET
      $PAND
      $ECOL
      $MS
      $FULC
      Environmental Services
      Public Utilities
      Investment Bankers/Brokers/Service
      Finance

    $PAND
    Financials

    Live finance-specific insights

    See more
    • Merck Completes Acquisition of Pandion Therapeutics

      KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND) at a purchase price of $60 per share. As of the tender offer expiration, 27,770,123 shares of common stock of Pandion were validly tendered and not withdrawn from the tender offer, representing approximately 88.6% percent of the outstanding common stock of Pandion on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck exp

      4/1/21 8:30:00 AM ET
      $PAND

    $PAND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: L. Joanne Viney decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:59:21 PM ET
      $PAND
    • SEC Form 4: Vikas Goyal decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:58:39 PM ET
      $PAND
    • SEC Form 4: L Alan Crane decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:57:32 PM ET
      $PAND

    $PAND
    SEC Filings

    See more
    • SEC Form 15-12B filed by Pandion Therapeutics Inc.

      15-12B - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/12/21 6:54:59 AM ET
      $PAND
    • SEC Form EFFECT filed by Pandion Therapeutics Inc.

      EFFECT - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/6/21 12:15:17 AM ET
      $PAND
    • SEC Form EFFECT filed by Pandion Therapeutics Inc.

      EFFECT - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/6/21 12:15:16 AM ET
      $PAND